Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 384

1.

Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.

Panzuto F, Puscedddu S, Faggiano A, Rinzivillo M, Brighi N, Prinzi N, Riccardi F, Iannicelli E, Maggio I, Femia D, Tafuto S, Manuzzi L, Di Sarno A, Annibale B, de Braud F, Campana D; Itanet (Italian Association for Neuroendocrine Tumours).

Pancreatology. 2019 Sep 30. pii: S1424-3903(19)30736-7. doi: 10.1016/j.pan.2019.09.015. [Epub ahead of print]

PMID:
31587962
2.

Non-conventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor.

Lamberti G, Faggiano A, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, Pusceddu S, Albertelli M, Massironi S, Panzuto F, Badalamenti G, Riccardi F, Butturini G, Gelsomino F, De Divitiis C, Modica R, Bongiovanni A, La Salvia A, Torchio M, Colao A, Ferone D, Campana D; ItaNet.

J Clin Endocrinol Metab. 2019 Sep 23. pii: dgz035. doi: 10.1210/clinem/dgz035. [Epub ahead of print]

PMID:
31545377
3.

Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431.

Mast KJ, Taub JW, Alonzo TA, Gamis AS, Mosse CA, Mathew P, Berman JN, Wang YC, Jones HM, Campana D, Coustan-Smith E, Raimondi SC, Hirsch B, Hitzler JK, Head DR.

Arch Pathol Lab Med. 2019 Aug 20. doi: 10.5858/arpa.2018-0526-OA. [Epub ahead of print]

PMID:
31429606
4.

The functioning side of the pancreas: a review on insulinomas.

Maggio I, Mollica V, Brighi N, Lamberti G, Manuzzi L, Ricci AD, Campana D.

J Endocrinol Invest. 2019 Jul 31. doi: 10.1007/s40618-019-01091-w. [Epub ahead of print] Review.

PMID:
31368049
5.

Cutaneous Scapular Lesion in an Elderly Woman.

Brighi N, Lamberti G, Campana D.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1754. [Epub ahead of print] No abstract available.

PMID:
31318376
6.

Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis.

Ricci C, Ingaldi C, Alberici L, Brighi N, Santini D, Mosconi C, Ambrosini V, Campana D, Minni F, Casadei R.

Endocrine. 2019 Jun 21. doi: 10.1007/s12020-019-01984-z. [Epub ahead of print]

PMID:
31227991
7.

Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study.

Panzuto F, Campana D, Massironi S, Faggiano A, Rinzivillo M, Lamberti G, Sciola V, Lahner E, Manuzzi L, Colao A, Annibale B.

Dig Liver Dis. 2019 Oct;51(10):1456-1460. doi: 10.1016/j.dld.2019.04.016. Epub 2019 Jun 5.

PMID:
31175013
8.

Incidental diagnosis of very small rectal neuroendocrine neoplasms: when should endoscopic submucosal dissection be performed? A single ENETS centre experience.

Pagano N, Ricci C, Brighi N, Ingaldi C, Pugliese F, Santini D, Campana D, Mosconi C, Ambrosini V, Casadei R.

Endocrine. 2019 Jul;65(1):207-212. doi: 10.1007/s12020-019-01907-y. Epub 2019 Mar 27.

PMID:
30919286
9.

Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes.

Brighi N, Lamberti G, Manuzzi L, Maggio I, Campana D.

Anticancer Drugs. 2019 Aug;30(7):e0784. doi: 10.1097/CAD.0000000000000784.

PMID:
30896503
10.

Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.

Kamiya T, Seow SV, Wong D, Robinson M, Campana D.

J Clin Invest. 2019 Mar 12;129(5):2094-2106. doi: 10.1172/JCI123955. Print 2019 May 1.

11.

No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy.

Robinson KM, Yang W, Karol SE, Kornegay N, Jay D, Cheng C, Choi JK, Campana D, Pui CH, Wood B, Borowitz MJ, Gastier-Foster J, Larsen EC, Winick N, Carroll WL, Loh ML, Raetz EA, Hunger SP, Devidas M, Mardis ER, Fulton RS, Relling MV, Jeha S.

Pediatr Blood Cancer. 2019 Jun;66(6):e27681. doi: 10.1002/pbc.27681. Epub 2019 Mar 7.

PMID:
30848065
12.

A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience.

Ricci C, Campana D, Casadei C, Ingaldi C, Ambrosini V, Pagano N, Santini D, Mosconi C, Brighi N, Alberici L, Minni F, Casadei R.

Endocrine. 2019 Jun;64(3):702-707. doi: 10.1007/s12020-019-01870-8. Epub 2019 Feb 22.

PMID:
30796689
13.

Derivation of combined species sensitivity distributions for acute toxicity of pyrethroids to aquatic animals.

Giddings JM, Wirtz J, Campana D, Dobbs M.

Ecotoxicology. 2019 Mar;28(2):242-250. doi: 10.1007/s10646-019-02018-0. Epub 2019 Feb 13.

PMID:
30758727
14.

Chromogranin A usefulness in small non-functioning pancreatic neuroendocrine tumors surgical management.

Lamberti G, Brighi N, Campana D.

Surgery. 2019 Jan 22. pii: S0039-6060(18)30828-6. doi: 10.1016/j.surg.2018.12.004. [Epub ahead of print] No abstract available.

PMID:
30683505
15.

68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma.

Tabacchi E, Campana D, Brighi N, Fanti S, Ambrosini V.

Clin Nucl Med. 2019 Mar;44(3):238-239. doi: 10.1097/RLU.0000000000002426.

PMID:
30672751
16.

Sex-specific influence of the vacuolar adenosine triphosphatase a2 isoform on outcome in twin pregnancies.

Sisti G, Di Tommaso M, Paccosi S, Parenti A, Di Rienzo G, Campana D, Witkin SS.

Am J Reprod Immunol. 2019 Jan;81(1):e13071. doi: 10.1111/aji.13071. Epub 2018 Nov 26.

PMID:
30418688
17.

Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study.

Brighi N, Lamberti G, Maggio I, Manuzzi L, Ricci C, Casadei R, Santini D, Mosconi C, Lisotti A, Ambrosini V, Pantaleo MA, Campana D.

Dig Liver Dis. 2019 May;51(5):689-694. doi: 10.1016/j.dld.2018.09.013. Epub 2018 Sep 24.

PMID:
30314949
18.

Comment on "Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors": A National Study From the French Group of Endocrine Tumors (GTE).

Lamberti G, Brighi N, Campana D.

Ann Surg. 2019 Aug;270(2):e43-e44. doi: 10.1097/SLA.0000000000003077. No abstract available.

PMID:
30312201
19.

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.

Di Giacinto P, Rota F, Rizza L, Campana D, Isidori A, Lania A, Lenzi A, Zuppi P, Baldelli R.

Int J Endocrinol. 2018 Jul 2;2018:8126087. doi: 10.1155/2018/8126087. eCollection 2018. Review.

20.

Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience.

Massironi S, Campana D, Partelli S, Panzuto F, Rossi RE, Faggiano A, Brighi N, Falconi M, Rinzivillo M, Delle Fave G, Colao AM, Conte D.

Ann Surg Oncol. 2018 Oct;25(11):3200-3206. doi: 10.1245/s10434-018-6673-5. Epub 2018 Jul 27.

PMID:
30054824
21.

Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study.

Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, Spada F, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, Vernieri C, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D.

Ann Surg. 2018 Jul 10. doi: 10.1097/SLA.0000000000002939. [Epub ahead of print]

PMID:
29995678
22.

Reverse-engineering flow-cytometry gating strategies for phenotypic labelling and high-performance cell sorting.

Becht E, Simoni Y, Coustan-Smith E, Evrard M, Cheng Y, Ng LG, Campana D, Newell EW.

Bioinformatics. 2019 Jan 15;35(2):301-308. doi: 10.1093/bioinformatics/bty491.

PMID:
29931307
23.

A novel λ integrase-mediated seamless vector transgenesis platform for therapeutic protein expression.

Makhija H, Roy S, Hoon S, Ghadessy FJ, Wong D, Jaiswal R, Campana D, Dröge P.

Nucleic Acids Res. 2018 Sep 19;46(16):e99. doi: 10.1093/nar/gky500.

24.

Universal monitoring of minimal residual disease in acute myeloid leukemia.

Coustan-Smith E, Song G, Shurtleff S, Yeoh AE, Chng WJ, Chen SP, Rubnitz JE, Pui CH, Downing JR, Campana D.

JCI Insight. 2018 May 3;3(9). pii: 98561. doi: 10.1172/jci.insight.98561.

25.

Data quality scoring system for microcosm and mesocosm studies used to derive a level of concern for atrazine.

Giddings JM, Campana D, Nair S, Brain R.

Integr Environ Assess Manag. 2018 Jul;14(4):489-497. doi: 10.1002/ieam.4050. Epub 2018 May 25.

PMID:
29663627
26.

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.

Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F.

Gastroenterology. 2018 Aug;155(2):479-489.e7. doi: 10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13.

PMID:
29655834
27.

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; NEPscore Working Group.

Endocr Relat Cancer. 2018 Jun;25(6):607-618. doi: 10.1530/ERC-17-0489. Epub 2018 Mar 20.

28.

Contraction of Surfactant-Laden Pores.

Lu J, Campana DM, Corvalan CM.

Langmuir. 2018 Apr 17;34(15):4701-4706. doi: 10.1021/acs.langmuir.8b00633. Epub 2018 Apr 6.

PMID:
29537842
29.

The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?

Lamberti G, Brighi N, Maggio I, Manuzzi L, Peterle C, Ambrosini V, Ricci C, Casadei R, Campana D.

Int J Mol Sci. 2018 Mar 6;19(3). pii: E747. doi: 10.3390/ijms19030747. Review.

30.

A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.

Kamiya T, Wong D, Png YT, Campana D.

Blood Adv. 2018 Mar 13;2(5):517-528. doi: 10.1182/bloodadvances.2017012823.

31.

Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis.

Ricci C, Casadei R, Taffurelli G, Campana D, Ambrosini V, Pacilio CA, Santini D, Brighi N, Minni F.

Pancreatology. 2018 Apr;18(3):313-317. doi: 10.1016/j.pan.2018.02.008. Epub 2018 Feb 21.

PMID:
29487026
32.

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.

Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconcini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F.

Pancreatology. 2018 Mar;18(2):198-203. doi: 10.1016/j.pan.2018.01.005. Epub 2018 Jan 12.

PMID:
29361429
33.

Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.

Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D.

Blood Adv. 2017 Nov 21;1(25):2348-2360. doi: 10.1182/bloodadvances.2017009928. eCollection 2017 Nov 28.

34.

Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors.

Lamberti G, Ceccarelli C, Brighi N, Maggio I, Santini D, Mosconi C, Ricci C, Biasco G, Campana D.

Gastroenterol Res Pract. 2017;2017:7872519. doi: 10.1155/2017/7872519. Epub 2017 Oct 29.

35.

Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.

Campana D, Walter T, Pusceddu S, Gelsomino F, Graillot E, Prinzi N, Spallanzani A, Fiorentino M, Barritault M, Dall'Olio F, Brighi N, Biasco G.

Endocrine. 2018 Jun;60(3):490-498. doi: 10.1007/s12020-017-1474-3. Epub 2017 Nov 17.

PMID:
29150792
36.

Minimal residual disease in pediatric ALL.

Pui CH, Campana D.

Oncotarget. 2017 Sep 13;8(45):78251-78252. doi: 10.18632/oncotarget.20856. eCollection 2017 Oct 3. No abstract available.

37.

Sporadic Small (≤20 mm) Nonfunctioning Pancreatic Neuroendocrine Neoplasm: is the Risk of Malignancy Negligible When Adopting a More Conservative Strategy? A Systematic Review and Meta-analysis.

Ricci C, Casadei R, Taffurelli G, Pacilio CA, Campana D, Ambrosini V, Donatella S, Minni F.

Ann Surg Oncol. 2017 Sep;24(9):2603-2610. doi: 10.1245/s10434-017-5946-8. Epub 2017 Jul 5. Review.

PMID:
28681158
38.

Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.

Brandi G, Paragona M, Campana D, Brighi N, Bondi A, Pantaleo MA, Corbelli J, Barbera MA, Biasco G.

J Chemother. 2018 Feb;30(1):53-58. doi: 10.1080/1120009X.2017.1340127. Epub 2017 Jun 22.

PMID:
28641483
39.

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.

Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS.

Blood. 2017 Jun 22;129(25):3304-3313. doi: 10.1182/blood-2017-01-764324. Epub 2017 Apr 7.

40.

Is surgery the best treatment for sporadic small (≤2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience.

Ricci C, Taffurelli G, Campana D, Ambrosini V, Pacilio CA, Pagano N, Santini D, Brighi N, Minni F, Casadei R.

Pancreatology. 2017 May - Jun;17(3):471-477. doi: 10.1016/j.pan.2017.03.004. Epub 2017 Mar 15.

PMID:
28320587
41.

The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia.

Eissa HM, Zhou Y, Panetta JC, Browne EK, Jeha S, Cheng C, Relling MV, Campana D, Pui CH, Inaba H.

Blood Cancer J. 2017 Feb 17;7(2):e531. doi: 10.1038/bcj.2017.11.

42.

Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study.

Davi' MV, Cosaro E, Piacentini S, Reimondo G, Albiger N, Arnaldi G, Faggiano A, Mantovani G, Fazio N, Piovesan A, Arvat E, Grimaldi F, Canu L, Mannelli M, Ambrogio AG, Pecori Giraldi F, Martini C, Lania A, Albertelli M, Ferone D, Zatelli MC, Campana D, Colao A, Scaroni C, Terzolo M, De Marinis L, Cingarlini S, Micciolo R, Francia G.

Eur J Endocrinol. 2017 Apr;176(4):453-461. doi: 10.1530/EJE-16-0809.

PMID:
28183788
43.

Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.

Campana D, Pui CH.

Blood. 2017 Apr 6;129(14):1913-1918. doi: 10.1182/blood-2016-12-725804. Epub 2017 Feb 6. Review. No abstract available.

44.

Everolimus in Pancreatic Neuroendocrine Carcinomas G3.

Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D, Fazio N, Delle Fave G.

Pancreas. 2017 Mar;46(3):302-305. doi: 10.1097/MPA.0000000000000762.

PMID:
28099254
45.

Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.

Huang YJ, Coustan-Smith E, Kao HW, Liu HC, Chen SH, Hsiao CC, Yang CP, Jaing TH, Yeh TC, Kuo MC, Lai CL, Chang CH, Campana D, Liang DC, Shih LY.

J Formos Med Assoc. 2017 Oct;116(10):774-781. doi: 10.1016/j.jfma.2016.12.002. Epub 2017 Jan 4.

46.

Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study.

Campana D, Ravizza D, Ferolla P, Faggiano A, Grimaldi F, Albertelli M, Ricci C, Santini D, Brighi N, Fazio N, Colao A, Ferone D, Tomassetti P.

Endocrine. 2017 Jun;56(3):633-638. doi: 10.1007/s12020-016-1099-y. Epub 2016 Sep 3.

PMID:
27592118
47.

Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Gruber TA, Leung WH, Yang JJ, Downing JR, Evans WE, Relling MV, Campana D.

Leukemia. 2017 Feb;31(2):333-339. doi: 10.1038/leu.2016.234. Epub 2016 Aug 18.

48.

Expanded and armed natural killer cells for cancer treatment.

Shimasaki N, Coustan-Smith E, Kamiya T, Campana D.

Cytotherapy. 2016 Nov;18(11):1422-1434. doi: 10.1016/j.jcyt.2016.06.013. Epub 2016 Aug 3. Review.

PMID:
27497701
49.

Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.

Wang W, Erbe AK, Alderson KA, Phillips E, Gallenberger M, Gan J, Campana D, Hank JA, Sondel PM.

Cancer Immunol Immunother. 2016 Sep;65(9):1047-59. doi: 10.1007/s00262-016-1864-z. Epub 2016 Jul 8.

50.

Time Dependence of the Electron and Positron Components of the Cosmic Radiation Measured by the PAMELA Experiment between July 2006 and December 2015.

Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carlson P, Casolino M, Castellini G, De Santis C, Di Felice V, Galper AM, Karelin AV, Koldashov SV, Koldobskiy SA, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergé M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Panico B, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev GI, Voronov SA, Yurkin YT, Zampa G, Zampa N, Potgieter MS, Vos EE.

Phys Rev Lett. 2016 Jun 17;116(24):241105. doi: 10.1103/PhysRevLett.116.241105. Epub 2016 Jun 17.

PMID:
27367381

Supplemental Content

Loading ...
Support Center